- Home
- DBVT vs THW Comparison
DBVT vs THW Comparison
Compare DBVT & THW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBVT
- THW
- Stock Information
- Founded
- DBVT 2002
- THW 2015
- Country
- DBVT France
- THW United States
- Employees
- DBVT N/A
- THW N/A
- Industry
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- THW Finance Companies
- Sector
- DBVT Health Care
- THW Finance
- Exchange
- DBVT Nasdaq
- THW Nasdaq
- Market Cap
- DBVT 464.0M
- THW 511.8M
- IPO Year
- DBVT N/A
- THW N/A
- Fundamental
- Price
- DBVT $14.36
- THW $11.94
- Analyst Decision
- DBVT Buy
- THW
- Analyst Count
- DBVT 5
- THW 0
- Target Price
- DBVT $15.85
- THW N/A
- AVG Volume (30 Days)
- DBVT 172.8K
- THW 149.9K
- Earning Date
- DBVT 10-28-2025
- THW 01-01-0001
- Dividend Yield
- DBVT N/A
- THW 10.76%
- EPS Growth
- DBVT N/A
- THW N/A
- EPS
- DBVT N/A
- THW N/A
- Revenue
- DBVT $5,502,000.00
- THW N/A
- Revenue This Year
- DBVT $1,743.46
- THW N/A
- Revenue Next Year
- DBVT $1,044.34
- THW N/A
- P/E Ratio
- DBVT N/A
- THW N/A
- Revenue Growth
- DBVT N/A
- THW N/A
- 52 Week Low
- DBVT $2.21
- THW $9.76
- 52 Week High
- DBVT $18.00
- THW $14.89
- Technical
- Relative Strength Index (RSI)
- DBVT 51.23
- THW 31.02
- Support Level
- DBVT $13.70
- THW $12.90
- Resistance Level
- DBVT $15.97
- THW $13.13
- Average True Range (ATR)
- DBVT 1.06
- THW 0.23
- MACD
- DBVT -0.40
- THW -0.13
- Stochastic Oscillator
- DBVT 15.71
- THW 3.25
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
About THW abrdn World Healthcare Fund Shares of Beneficial Interest
Tekla World Healthcare Fund is a diversified closed-end management investment company. Its investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies engaged in the healthcare industry. The company's investment portfolio comprises investments in different sub-sectors such as pharmaceuticals and biotechnology, healthcare providers and services, real estate investment trusts, medical devices and diagnostics, and other areas. It also male into REIT Real Estate.